Antihyperglycaemic drugs effective for treating NAFLD, review finds
Combination therapy could be a "particularly effective therapeutic option", researchers say
Three different classes of antihyperglycaemic drugs have shown promise in improving liver function in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, according to a systematic review.
Pending larger phase III trials, peroxisome proliferator-activated receptor (PPAR) agonists, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors could become vital treatment options for these conditions, European researchers say.
Writing in The Lancet
